The subcutaneous formulation is not just an alternative but should be considered the new standard of care for any patient eligible for amivantamab, regardless of the specific regimen. Its benefits are so significant that it may even expand the eligible patient pool to those previously hesitant due to long infusion times or reaction fears.
The primary advantage of subcutaneous amivantamab extends beyond clinical safety to operational efficiency and patient well-being. It significantly reduces infusion time, freeing up limited oncology clinic resources and, more importantly, allowing patients with a limited life expectancy to spend less time in treatment and more with loved ones.
While designed to prove non-inferiority, the PALOMA-3 trial unexpectedly suggested that the subcutaneous formulation might improve overall survival compared to the IV version. Although the study wasn't powered to confirm this finding and the reason is unclear, it serves as a powerful, reassuring point for clinicians discussing treatment options with patients.